HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $33 Price Target
Purple Biotech Analyst Ratings
HC Wainwright & Co. Maintains Buy on Purple Biotech, Adjusts Price Target To $33 (1-20 Reverse Stock Split)
Purple Biotech Analyst Ratings
H.C. Wainwright Maintains Purple Biotech(PPBT.US) With Buy Rating, Cuts Target Price to $33
Analysts Offer Insights on Healthcare Companies: Purple Biotech (PPBT) and Aligos Therapeutics (ALGS)
Purple Biotech Analyst Ratings
Purple Biotech Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $10 Price Target
Promising Phase 2 Results for Purple Biotech's CM24 in Pancreatic Cancer Treatment Bolster Buy Rating
Buy Rating Justified by Purple Biotech's Promising Clinical Data and Market Potential
HC Wainwright & Co. : The Purple Biotech (PPBT.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
Purple Biotech Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $10 Price Target
HC Wainwright & Co. : The Purple Biotech (PPBT.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
Purple Biotech Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $10 Price Target
Purple Biotech Analyst Ratings
Purple Biotech Analyst Ratings
Promising Pipeline Prospects for Purple Biotech: Buy Rating Affirmed Amidst Anticipated Clinical Advancements